France's Centre National De Genotypage Purchases Production-
2004-02-25 12:38 (New York)
Scale SNP Genotyping BeadLab from Illumina
Health/Medical Writers / Business Editors
BIOWIRE2K
SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2004
Illumina's BeadArray(TM) Technology to Enable Expanded Scale of
Research for Identifying Genes Associated with Hereditary Diseases
Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with
the Centre National de Genotypage (CNG), located in Evry, France, for
the purchase of an Illumina(R) BeadLab. The BeadLab, a
production-scale SNP (single nucleotide polymorphism) genotyping
laboratory, will constitute an integral component of the Centre's
state-of-the-art capabilities devoted to understanding the functional
implications of sequence variation in the human genome and other model
organisms.
The BeadLab will be installed at CNG's Evry research campus near
Paris and used to conduct large-scale genotyping projects in
collaboration with research groups at the national, European, or
international level covering a variety of inherited diseases including
diabetes and hypertension. These large projects will help researchers
understand the role of genetic variation in disease susceptibility and
facilitate the identification of genes associated with inherited
diseases.
The BeadLab is an end-to-end genotyping solution built around
Illumina's proprietary BeadArray(TM) technology and featuring high
sample throughput, low running cost per SNP scored and
industry-leading performance. When installed, the genotyping
laboratory at CNG will have the capacity to produce routinely over
eight hundred thousand genotypes per day.
"CNG is a world leader in genetic research and we look forward to
developing a strong, collaborative relationship," stated Jay Flatley,
Illumina President and CEO. "Our genotyping BeadLab will expand
significantly the potential scale of genomics research conducted at
CNG and help the Centre's investigators and colleagues better
understand the complex relationships between genetics and disease."
CNG is a part of the CNRG (Consortium National de Recherche en
Genomique). In addition to CNG, CNRG members include CNS (Centre
National de Sequencage) and the Genopole(R). Additional information
about the Centre National de Genotypage can be found at
cng.fr.
Illumina (www.illumina.com) is developing next-generation tools
for the large-scale analysis of genetic variation and function. The
Company's proprietary BeadArray technology -- now used in leading
genomics centers around the world -- provides the throughput, cost
effectiveness and flexibility necessary to enable researchers in the
life sciences and pharmaceutical industries to perform the billions of
tests necessary to extract medically valuable information from
advances in genomics and proteomics. This information will help pave
the way to personalized medicine by correlating genetic variation and
gene function with particular disease states, enhancing drug
discovery, allowing diseases to be detected earlier and more
specifically, and permitting better choices of drugs for individual
patients. |
